Skip to content

Search Results

No Matching Results

    Recently Viewed

      Listening...

      HomeMedia CenterPress releases PharmaceuticalsScios Inc. Announces Agreement with Department of Justice Regarding NATRECOR®

      Scios Inc. Announces Agreement with Department of Justice Regarding NATRECOR®

      Share Article
      share to

      Raritan, NJ (October 5, 2011) – Today Scios Inc. announced an agreement with the United States Department of Justice to resolve allegations of misbranding of NATRECOR® (nesiritide), a prescription medication for patients with heart failure.

      As part of this agreement, Scios Inc. entered a guilty plea to a single misdemeanor violation of the Food, Drug and Cosmetic Act, and agreed to pay an $85 million fine.

      Scios acknowledges that NATRECOR® was misbranded and used in a way not approved by the U.S. Food and Drug Administration because its labeling lacked adequate directions for that use, but denies any wrongful intent in connection with this plea.

      ###

      Contact:
      Media:
      Shaun Mickus
      Office: (908) 927-2416
      smickus@its.jnj.com

      Bill Foster
      Cell: (908) 392-6057
      wfoster@its.jnj.com

      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.